Prevention is collapsing at the moment a breakthrough drug is finally within reach
A year after the fracture in global HIV funding, the Clinton Health Access Initiative has released data confirming what many feared: the wound has not closed, it has widened. Across sub-Saharan Africa and Asia, the infrastructure of testing, treatment, and prevention has continued to erode rather than recover, leaving children without antiretroviral therapy and communities without the tools to stop new infections. The cruelest irony is that a breakthrough HIV drug now stands ready for deployment into systems that are quietly coming apart. What the data asks of us is not merely attention, but the recognition that decades of hard-won progress exist on a continuum — and that continuum can run in reverse.
- A full year after the funding crisis began, HIV services across sub-Saharan Africa and Asia have not stabilized — they have kept declining.
- Children are falling out of treatment programs first, as pediatric HIV care contracts and caregivers find clinics reduced or closed.
- Prevention infrastructure — the first line of defense against new infections — is collapsing at precisely the moment treatment capacity can least absorb a surge in cases.
- A breakthrough HIV drug is now available for deployment, but the health worker networks, supply chains, and clinics needed to deliver it are fragmenting.
- CHAI's June 2026 memo frames this not as a temporary disruption but as compounding institutional damage — closed clinics, scattered expertise, broken supply lines.
- Sustained funding recovery and immediate intervention are the only paths to arresting deterioration before the losses of decades become permanent.
A year has passed since the global funding machinery for HIV care began to fail, and the Clinton Health Access Initiative has now produced the first comprehensive accounting of what that rupture has cost. The picture is not one of a system paused and waiting to resume. It is one of continued deterioration.
CHAI's HIV Market Impact Memo, released in June 2026, tracks testing, treatment, and prevention programs across sub-Saharan Africa and Asia through 2025 and into early 2026. Testing rates have remained depressed — not temporarily dipped, but sustained at levels below what the HIV response requires. When people do not learn their status, they cannot access treatment, and they remain infectious. The epidemiological logic is unforgiving.
For children, the situation is more acute still. Pediatric patients depend entirely on caregivers and functioning health systems to reach care, and they are typically the first to fall out when programs contract. CHAI's data confirms this is happening. Treatment access for children has not improved across the regions tracked.
Prevention programs — pre-exposure prophylaxis, harm reduction, sexual health services — are collapsing at the worst possible moment. Prevention is always the first casualty of funding cuts, because its benefits are measured in infections that never occur. Yet it becomes most critical precisely when treatment systems are shrinking and cannot absorb new cases.
The particular cruelty of this moment is that a breakthrough HIV drug has become available for deployment just as the systems needed to deliver it are coming apart. Clinics have closed or reduced hours. Health workers have left the field. Supply chains have broken. The institutional knowledge that makes HIV programs function has begun to scatter.
What CHAI's data makes plain is that the damage from the initial crisis has not been arrested — it has compounded. The question now is whether the system can be rebuilt before that damage becomes irreversible.
A year has passed since the global machinery that funds HIV care began to seize. The Clinton Health Access Initiative has now collected the first comprehensive accounting of what that rupture actually cost, and the picture is grimmer than a simple pause would suggest. Across sub-Saharan Africa and Asia, HIV services have not bounced back. They have continued to deteriorate.
The data, compiled into CHAI's HIV Market Impact Memo released in June 2026, tracks the trajectory of testing, treatment, and prevention programs through 2025 and into the first months of 2026—measuring them against the year before the funding crisis took hold. What emerges is a portrait of cascading failure. People are not walking into clinics to learn their status. Children who need antiretroviral therapy are not receiving it. The prevention infrastructure that might have contained new infections is coming apart.
The timing of this collapse carries a particular cruelty. Just as a breakthrough HIV drug has become available for actual deployment—a scientific achievement that should have opened new possibilities for treatment and prevention—the systems needed to deliver it are fragmenting. The promise of the drug means nothing if the networks that would distribute it, the clinics that would prescribe it, and the health workers trained to administer it have already begun to fail.
Testing rates tell the story most plainly. When people do not get tested, they do not know their status. When they do not know their status, they cannot access treatment. When they do not access treatment, they remain infectious. The epidemiological logic is brutal and simple. CHAI's data shows testing has remained depressed throughout the period—it has not recovered to pre-crisis levels. This is not a temporary dip. This is a sustained absence of the basic diagnostic infrastructure that HIV response depends on.
The situation for children is even more acute. Treatment access for pediatric patients has not improved. Children represent a particularly vulnerable population in HIV epidemiology—they cannot advocate for themselves, they depend entirely on caregivers and health systems to connect them to care, and the window for intervention is narrow. When treatment programs contract, children are often the first to fall out of the system. CHAI's data confirms this pattern is holding across the regions they tracked.
Prevention programs face their own collapse. These are the interventions meant to stop new infections before they start—pre-exposure prophylaxis, harm reduction services, sexual health education, and other evidence-based approaches. They are resource-intensive and politically vulnerable. When funding dries up, prevention is typically the first thing cut, because its benefits accrue over time and are measured in infections that do not happen—harder to defend than treatment, which saves visible lives in the present. The irony is that prevention becomes most urgent precisely when treatment capacity is shrinking, because the system cannot absorb a surge in new cases.
What CHAI's memo documents is not a temporary disruption followed by recovery. It is a year-long failure of the funding mechanisms to restore themselves, coupled with the continued deterioration of the services that depend on them. The data suggests that the damage from the initial crisis has not been arrested. Instead, it has compounded. Clinics have closed or reduced hours. Health workers have left the field. Supply chains have broken. The institutional knowledge and relationships that make HIV programs work have begun to scatter.
The question now is whether the system can be rebuilt before the damage becomes irreversible. CHAI's data provides the evidence that intervention is urgent. Without sustained funding recovery and immediate action to shore up testing, treatment, and prevention infrastructure, the gains made over decades of HIV response are at risk of being undone.
Notable Quotes
Services have not recovered; people are not getting tested, children are not getting treatment, and prevention is collapsing at the moment a breakthrough drug is finally within reach.— Clinton Health Access Initiative HIV Market Impact Memo, June 2026
The Hearth Conversation Another angle on the story
When you say services have not recovered, what does that actually look like on the ground? Are clinics closed, or are they open but empty?
Both, in different places. Some clinics have reduced their hours or cut staff. Others are still operating but they're running on fumes—fewer tests being done, longer waits, less reliable supply of medications. The infrastructure is still there in some cases, but it's degraded.
And the children not getting treatment—is that because the drugs aren't available, or because families can't reach the clinics?
It's usually both. Supply chains have broken down, so drugs aren't always there. But also, when a health system is under stress, pediatric services often get deprioritized. Children need more intensive management, more follow-up. When resources shrink, that's expensive to maintain.
The memo mentions a breakthrough drug. Why does that matter if the system to deliver it is falling apart?
Because you can have the best medicine in the world, but if there's no one to prescribe it, no way to get it to patients, no clinic for them to go to—it doesn't exist for them. The drug is only useful if the system that surrounds it is functional.
Is there any sign that funding is coming back, or are we looking at a permanent contraction?
The data only goes through early 2026. There's no indication yet of recovery. What's clear is that the damage from the initial crisis didn't stop when the funding crisis began—it's kept going, deepening. That suggests we're not in a holding pattern. We're in a decline.
What happens if this continues for another year?
You lose more health workers. Clinics close permanently instead of temporarily. The networks that connect patients to care dissolve. And epidemiologically, you get more new infections, more advanced disease, more deaths. The system becomes harder to rebuild the longer it's broken.